Benvenue Medical closes $35M Series C funding for clinical trial of their new VCF system |

Benvenue Medical closes $35M Series C funding for clinical trial of their new VCF system

Kiva animation link

Benvenue Medical Closes $35.5 Million Series C Financing (press release)

Benvenue Medical, Inc., a developer of minimally invasive solutions for spine repair, announced the completion of a $35.5 million Series C round of financing.  The proceeds will be used to complete KAST (Kiva® System as a Vertebral Augmentation Treatment – ASafety and Effectiveness Trial) and execute on the company’s commercialization strategy.  Benvenue Medical is entering a $9 billion global spinal device market with three breakthrough minimally invasive products to treat vertebral compression fractures (VCFs) and degenerative disc disease (DDD).

 

 

Leave a Reply

Your email address will not be published. Required fields are marked *